3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Osteosarcoma
3
Neuroblastoma
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive
1
Nerve Sheath Neoplasms
1
Neoplasm Metastasis
1
Myoepithelioma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Hodgkin Disease
1
Giant Cell Tumor of Bone
1
Desmoplastic Small Round Cell Tumor
1
Clear-cell metastatic renal cell carcinoma
1
Chordoma
1
Chondrosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Metastatic
1
Interventions
Oxaliplatin
64
pembrolizumab
48
Fluorouracil
44
Capecitabine
38
Nivolumab
33
Leucovorin
32
Paclitaxel
28
Trastuzumab
19
Docetaxel
18
Cisplatin
18
S 1 (combination)
16
Bevacizumab
15
Ramucirumab
13
Irinotecan
13
Drug Therapy
13
tislelizumab
12
Cyclophosphamide
12
fludarabine
10
Carboplatin
10
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
8
sintilimab
8
Specimen Handling
8
Biopsy
8
atezolizumab
7
Surgical Procedures, Operative
7
Gemcitabine
7
zolbetuximab
6
durvalumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Zoledronic Acid
×
1 year
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled